(Information sent by the signatory company)
-The new immunogenicity risk assessment platform, ISPRI, facilitates the development of biological therapies
PROVIDENCE, R.I., April 1, 2024 /PRNewswire/ -- In pursuit of the development of new biological entities, scientists harnessing the power of AI and generative biology rely on computational tools to predict and manage the risk of immunogenicity, a critical characterization step in the candidate development process to ensure drug efficacy and safety prior to clinical trials. Today marks significant progress in this effort with the publication of "In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies" in mAbs, which describes the ISPRI (Immunogenicity Screening and Protein Re-engineering Interface) toolkit, a web-based platform for in silico immunogenicity risk assessment of biologic therapies in preclinical development stages.
Developed over many years by bioinformaticians at EpiVax, ISPRI provides researchers with a secure interface composed of integrated computational tools that enable a systematic approach to expedite the evaluation and mitigation of immunogenic potential and accelerate overall preclinical development efforts.
The tools, each playing a critically important role in the screening process, include: EpiMatrix for T cell epitope mapping, ClustiMer for identification of epitope-dense regions that could be key to further testing/ deimmunization, JanusMatrix for epitope characterization (the identification of potentially tolerated or actively tolerogenic epitopes, such as Tregitopes), and OptiMatrix for sequence modifications to mitigate immunogenic risks.
In particular, ISPRI tools can be applied at different stages of development, from early-stage discovery for high-throughput hit screening, to comprehensive evaluation of a lead candidate in preparation for IND submission and development of an Integrated Summary of Immunogenicity (ISI).
Additionally, the toolkit is useful for the screening of all biological therapeutic modalities, from monoclonal antibodies to bispecific, multispecific, antibody-drug conjugates, enzyme replacement proteins, CAR-T, gene therapy products, and peptide drugs.
Annie De Groot, MD, Chief Scientific Officer, emphasized the importance of ISPRI in advancing the development of biologic therapies, stating, "ISPRI stands as a critical tool in the search for safer and more effective biologic therapies, enabling "Researchers navigate the complexities of immunogenicity with precision and confidence."
About EpiVax:
EpiVax, a 26-year-old biotechnology company located in Providence, Rhode Island, is a leader in the field of evaluating the immunogenicity of biologics and vaccines. EpiVax partners with a global roster of companies, agencies and academics to accelerate immunogenicity risk assessment by providing access to advanced computational immunology tools, such as the ISPRI and iVAX toolkits, for research across a range of applications.
Press contact:
Sarah Moniz, Associate Director of Business Development, EpiVax, Inc.smoniz@epivax.com
Logo - https://mma.prnewswire.com/media/542055/...
View original content: https://www.prnewswire.com/news-releases/plataforma-de-evaluacion-de-riesgos-de-inmunogenicidad-ispri-facilita-el-desarrollo-de-terapias-biologicas-302103949.html
